United States

People: Cempra Inc (CEMP.O)

CEMP.O on Nasdaq

25 Sep 2017
Change (% chg)

$-0.00 (-0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Goldstein, Dov 

Dr. Dov A. Goldstein, M.D., is an Independent Director of Cempra, Inc. since January 2008. He has been a partner at Aisling Capital, a private investment firm, since 2008. From 2006 to 2008, he was a Principal at Aisling Capital. From July 2014 to January 2015, he served as Chief Financial Officer of Loxo Oncology(NASDAQ:LOXO) and an Operating Partner at Aisling Capital. In January 2015, he became a Partner again at Aisling Capital and the Acting Chief Financial Officer at Loxo Oncology (NASDAQ:LOXO). From 2000 to 2005, Dr. Goldstein was Chief Financial Officer of Vicuron Pharmaceuticals, Inc. (NASDAQ: MICU) (acquired by Pfizer Inc.). From 1998 to 2000, Dr. Goldstein was Director of Venture Analysis at HealthCare Ventures, a privately held investment fund. Dr. Goldstein serves on the board of directors of several publicly reporting pharmaceutical companies, namely ADMA Biologics, Inc. (OTCQB; ADMA) and Esperion Therapeutics, Inc. (NASDAQ: ESPR). Dr. Goldstein has also served on the board of Loxo Oncology (NASDAQ:LOXO) and Durata Therapeutics (NASDAQ:DRTX). He holds a B.S. in biology from Stanford University, an M.D. from the Yale School of Medicine and an M.B.A. from the Columbia Business School.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --